Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of Europ...
Gespeichert in:
| Veröffentlicht in: | The Lancet. Haematology 2022-05, Vol.9 (5), p.e340-e349 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e349 |
|---|---|
| container_issue | 5 |
| container_start_page | e340 |
| container_title | The Lancet. Haematology |
| container_volume | 9 |
| creator | El-Khoury, Habib Lee, David J Alberge, Jean-Baptiste Redd, Robert Cea-Curry, Christian J Perry, Jacqueline Barr, Hadley Murphy, Ciara Sakrikar, Dhananjay Barnidge, David Bustoros, Mark Leblebjian, Houry Cowan, Anna Davis, Maya I Amstutz, Julia Boehner, Cody J Lightbody, Elizabeth D Sklavenitis-Pistofidis, Romanos Perkins, Mark C Harding, Stephen Mo, Clifton C Kapoor, Prashant Mikhael, Joseph Borrello, Ivan M Fonseca, Rafael Weiss, Scott T Karlson, Elizabeth Trippa, Lorenzo Rebbeck, Timothy R Getz, Gad Marinac, Catherine R Ghobrial, Irene M |
| description | Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of European ancestry aged 50 years or older. MGUS prevalence is two times higher in individuals of African descent or with a family history of conditions related to multiple myeloma. We aimed to evaluate the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population screened by quantitative mass spectrometry.
We used quantitative matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry and EXENT-iQ software to screen for and quantify monoclonal gammopathies in serum from 7622 individuals who consented to the PROMISE screening study between Feb 26, 2019, and Nov 4, 2021, and the Mass General Brigham Biobank (MGBB) between July 28, 2010, and July 1, 2021. M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were confirmed by liquid chromatography mass spectrometry testing. 6305 (83%; 2211 from PROMISE, 4094 from MGBB) of 7622 participants in the cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a family history of haematological malignancies and fell within the eligible high-risk age range (30 years or older for PROMISE cohort and 18 years or older for MGBB cohort); those over 18 years were also eligible if they had two or more family members with a blood cancer (PROMISE cohort). Participants with a plasma cell malignancy diagnosed before screening were excluded. Longitudinal clinical data were available for MGBB participants with a median follow-up time from serum sample screening of 4·5 years (IQR 2·4–6·7). The PROMISE study is registered with ClinicalTrials.gov, NCT03689595.
The median age at time of screening was 56·0 years (IQR 46·8–64·1). 5013 (66%) of 7622 participants were female, 2570 (34%) male, and 39 ( |
| doi_str_mv | 10.1016/S2352-3026(22)00069-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2644962980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2352302622000692</els_id><sourcerecordid>2644962980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-1b58683c0292a5d16f16ca24aab9bbccbdf7a448bc9159398183d5f4f19c60933</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhS0EolXpI4C8LIu0_ondmA1CVaGVKoFUuracidNr8E-wnUr3NXhifHtLxY6VRzPf8WjOQegtJaeUUHl2y7hgHSdMnjD2nhAiVcdeoMPn9st_6gN0XMqPBlF-LoVUr9EBF7zv5aAO0e9v2T4YbyNYnGYcUkzgUzQe35sQ0mLqxtmCTZwweBcdtElaK6TQui5igzfuftNlV37iu1u8pGX1proUcYFsbbQTHrc4mFJwWSzU3IQ1bz80YVh9dWBjzRZD2qRccanrtH2DXs3GF3v89B6hu8-X3y-uupuvX64vPt10wKWoHR3FIAcOhClmxETlTCUY1hszqnEEGKf53PT9MIKiQnE10IFPYu5nqkASxfkROtn_u-T0a7Wl6uAKWO9NtGktmsm-V5KpgTRU7FHIqZRsZ71kF0zeakr0LhH9mIje2a0Z04-JaNZ0755WrGOw07Pqr_8N-LgHbDv0wdmsC7hdGJPLzS09JfefFX8Acu2drw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644962980</pqid></control><display><type>article</type><title>Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>El-Khoury, Habib ; Lee, David J ; Alberge, Jean-Baptiste ; Redd, Robert ; Cea-Curry, Christian J ; Perry, Jacqueline ; Barr, Hadley ; Murphy, Ciara ; Sakrikar, Dhananjay ; Barnidge, David ; Bustoros, Mark ; Leblebjian, Houry ; Cowan, Anna ; Davis, Maya I ; Amstutz, Julia ; Boehner, Cody J ; Lightbody, Elizabeth D ; Sklavenitis-Pistofidis, Romanos ; Perkins, Mark C ; Harding, Stephen ; Mo, Clifton C ; Kapoor, Prashant ; Mikhael, Joseph ; Borrello, Ivan M ; Fonseca, Rafael ; Weiss, Scott T ; Karlson, Elizabeth ; Trippa, Lorenzo ; Rebbeck, Timothy R ; Getz, Gad ; Marinac, Catherine R ; Ghobrial, Irene M</creator><creatorcontrib>El-Khoury, Habib ; Lee, David J ; Alberge, Jean-Baptiste ; Redd, Robert ; Cea-Curry, Christian J ; Perry, Jacqueline ; Barr, Hadley ; Murphy, Ciara ; Sakrikar, Dhananjay ; Barnidge, David ; Bustoros, Mark ; Leblebjian, Houry ; Cowan, Anna ; Davis, Maya I ; Amstutz, Julia ; Boehner, Cody J ; Lightbody, Elizabeth D ; Sklavenitis-Pistofidis, Romanos ; Perkins, Mark C ; Harding, Stephen ; Mo, Clifton C ; Kapoor, Prashant ; Mikhael, Joseph ; Borrello, Ivan M ; Fonseca, Rafael ; Weiss, Scott T ; Karlson, Elizabeth ; Trippa, Lorenzo ; Rebbeck, Timothy R ; Getz, Gad ; Marinac, Catherine R ; Ghobrial, Irene M</creatorcontrib><description>Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of European ancestry aged 50 years or older. MGUS prevalence is two times higher in individuals of African descent or with a family history of conditions related to multiple myeloma. We aimed to evaluate the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population screened by quantitative mass spectrometry.
We used quantitative matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry and EXENT-iQ software to screen for and quantify monoclonal gammopathies in serum from 7622 individuals who consented to the PROMISE screening study between Feb 26, 2019, and Nov 4, 2021, and the Mass General Brigham Biobank (MGBB) between July 28, 2010, and July 1, 2021. M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were confirmed by liquid chromatography mass spectrometry testing. 6305 (83%; 2211 from PROMISE, 4094 from MGBB) of 7622 participants in the cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a family history of haematological malignancies and fell within the eligible high-risk age range (30 years or older for PROMISE cohort and 18 years or older for MGBB cohort); those over 18 years were also eligible if they had two or more family members with a blood cancer (PROMISE cohort). Participants with a plasma cell malignancy diagnosed before screening were excluded. Longitudinal clinical data were available for MGBB participants with a median follow-up time from serum sample screening of 4·5 years (IQR 2·4–6·7). The PROMISE study is registered with ClinicalTrials.gov, NCT03689595.
The median age at time of screening was 56·0 years (IQR 46·8–64·1). 5013 (66%) of 7622 participants were female, 2570 (34%) male, and 39 (<1%) unknown. 2439 (32%) self-identified as Black, 4986 (65%) as White, 119 (2%) as other, and 78 (1%) unknown. Using serum protein electrophoresis with immunofixation electrophoresis, the MGUS prevalence was 6% (101 of 1714) in high-risk individuals aged 50 years or older. Using mass spectrometry, we observed a total prevalence of monoclonal gammopathies of 43% (1788 of 4207) in this group. We termed monoclonal gammopathies below the clinical immunofixation electrophoresis detection level (<0·2 g/L) MGIPs, to differentiate them from those with higher concentrations, termed mass-spectrometry MGUS, which had a 13% (592 of 4207) prevalence by mass spectrometry in high-risk individuals aged 50 years or older. MGIP was predominantly of immunoglobulin M isotype, and its prevalence increased with age (19% [488 of 2564] for individuals aged <50 years, 29% [1464 of 5058] for those aged ≥50 years, and 37% [347 of 946] for those aged ≥70 years). Mass-spectrometry MGUS prevalence increased with age (5% [127 of 2564] for individuals aged <50 years, 13% [678 of 5058] for those aged ≥50 years, and 18% [173 of 946] for those aged ≥70 years) and was higher in men (314 [12%] of 2570) compared with women (485 [10%] 5013; p=0·0002), whereas MGIP prevalence did not differ significantly by gender. In those aged 50 years or older, the prevalence of mass spectrometry was significantly higher in Black participants (224 [17%] of 1356) compared with the controls (p=0·0012) but not in those with family history (368 [13%] of 2851) compared with the controls (p=0·1008). Screen-detected monoclonal gammopathies correlated with increased all-cause mortality in MGBB participants (hazard ratio 1·55, 95% CI 1·16–2·08; p=0·0035). All monoclonal gammopathies were associated with an increased likelihood of comorbidities, including myocardial infarction (odds ratio 1·60, 95% CI 1·26–2·02; p=0·00016 for MGIP-high and 1·39, 1·07–1·80; p=0·015 for mass-spectrometry MGUS).
We detected a high prevalence of monoclonal gammopathies, including age-associated MGIP, and made more precise estimates of mass-spectrometry MGUS compared with conventional gel-based methods. The use of mass spectrometry also highlighted the potential hidden clinical significance of MGIP. Our study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival.
Stand Up To Cancer Dream Team, the Multiple Myeloma Research Foundation, and National Institutes of Health.</description><identifier>ISSN: 2352-3026</identifier><identifier>EISSN: 2352-3026</identifier><identifier>DOI: 10.1016/S2352-3026(22)00069-2</identifier><identifier>PMID: 35344689</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cohort Studies ; Female ; Humans ; Male ; Mass Spectrometry ; Monoclonal Gammopathy of Undetermined Significance - epidemiology ; Multiple Myeloma - epidemiology ; Paraproteinemias - diagnosis ; Paraproteinemias - epidemiology ; Prevalence</subject><ispartof>The Lancet. Haematology, 2022-05, Vol.9 (5), p.e340-e349</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-1b58683c0292a5d16f16ca24aab9bbccbdf7a448bc9159398183d5f4f19c60933</citedby><cites>FETCH-LOGICAL-c365t-1b58683c0292a5d16f16ca24aab9bbccbdf7a448bc9159398183d5f4f19c60933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35344689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El-Khoury, Habib</creatorcontrib><creatorcontrib>Lee, David J</creatorcontrib><creatorcontrib>Alberge, Jean-Baptiste</creatorcontrib><creatorcontrib>Redd, Robert</creatorcontrib><creatorcontrib>Cea-Curry, Christian J</creatorcontrib><creatorcontrib>Perry, Jacqueline</creatorcontrib><creatorcontrib>Barr, Hadley</creatorcontrib><creatorcontrib>Murphy, Ciara</creatorcontrib><creatorcontrib>Sakrikar, Dhananjay</creatorcontrib><creatorcontrib>Barnidge, David</creatorcontrib><creatorcontrib>Bustoros, Mark</creatorcontrib><creatorcontrib>Leblebjian, Houry</creatorcontrib><creatorcontrib>Cowan, Anna</creatorcontrib><creatorcontrib>Davis, Maya I</creatorcontrib><creatorcontrib>Amstutz, Julia</creatorcontrib><creatorcontrib>Boehner, Cody J</creatorcontrib><creatorcontrib>Lightbody, Elizabeth D</creatorcontrib><creatorcontrib>Sklavenitis-Pistofidis, Romanos</creatorcontrib><creatorcontrib>Perkins, Mark C</creatorcontrib><creatorcontrib>Harding, Stephen</creatorcontrib><creatorcontrib>Mo, Clifton C</creatorcontrib><creatorcontrib>Kapoor, Prashant</creatorcontrib><creatorcontrib>Mikhael, Joseph</creatorcontrib><creatorcontrib>Borrello, Ivan M</creatorcontrib><creatorcontrib>Fonseca, Rafael</creatorcontrib><creatorcontrib>Weiss, Scott T</creatorcontrib><creatorcontrib>Karlson, Elizabeth</creatorcontrib><creatorcontrib>Trippa, Lorenzo</creatorcontrib><creatorcontrib>Rebbeck, Timothy R</creatorcontrib><creatorcontrib>Getz, Gad</creatorcontrib><creatorcontrib>Marinac, Catherine R</creatorcontrib><creatorcontrib>Ghobrial, Irene M</creatorcontrib><title>Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study</title><title>The Lancet. Haematology</title><addtitle>Lancet Haematol</addtitle><description>Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of European ancestry aged 50 years or older. MGUS prevalence is two times higher in individuals of African descent or with a family history of conditions related to multiple myeloma. We aimed to evaluate the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population screened by quantitative mass spectrometry.
We used quantitative matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry and EXENT-iQ software to screen for and quantify monoclonal gammopathies in serum from 7622 individuals who consented to the PROMISE screening study between Feb 26, 2019, and Nov 4, 2021, and the Mass General Brigham Biobank (MGBB) between July 28, 2010, and July 1, 2021. M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were confirmed by liquid chromatography mass spectrometry testing. 6305 (83%; 2211 from PROMISE, 4094 from MGBB) of 7622 participants in the cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a family history of haematological malignancies and fell within the eligible high-risk age range (30 years or older for PROMISE cohort and 18 years or older for MGBB cohort); those over 18 years were also eligible if they had two or more family members with a blood cancer (PROMISE cohort). Participants with a plasma cell malignancy diagnosed before screening were excluded. Longitudinal clinical data were available for MGBB participants with a median follow-up time from serum sample screening of 4·5 years (IQR 2·4–6·7). The PROMISE study is registered with ClinicalTrials.gov, NCT03689595.
The median age at time of screening was 56·0 years (IQR 46·8–64·1). 5013 (66%) of 7622 participants were female, 2570 (34%) male, and 39 (<1%) unknown. 2439 (32%) self-identified as Black, 4986 (65%) as White, 119 (2%) as other, and 78 (1%) unknown. Using serum protein electrophoresis with immunofixation electrophoresis, the MGUS prevalence was 6% (101 of 1714) in high-risk individuals aged 50 years or older. Using mass spectrometry, we observed a total prevalence of monoclonal gammopathies of 43% (1788 of 4207) in this group. We termed monoclonal gammopathies below the clinical immunofixation electrophoresis detection level (<0·2 g/L) MGIPs, to differentiate them from those with higher concentrations, termed mass-spectrometry MGUS, which had a 13% (592 of 4207) prevalence by mass spectrometry in high-risk individuals aged 50 years or older. MGIP was predominantly of immunoglobulin M isotype, and its prevalence increased with age (19% [488 of 2564] for individuals aged <50 years, 29% [1464 of 5058] for those aged ≥50 years, and 37% [347 of 946] for those aged ≥70 years). Mass-spectrometry MGUS prevalence increased with age (5% [127 of 2564] for individuals aged <50 years, 13% [678 of 5058] for those aged ≥50 years, and 18% [173 of 946] for those aged ≥70 years) and was higher in men (314 [12%] of 2570) compared with women (485 [10%] 5013; p=0·0002), whereas MGIP prevalence did not differ significantly by gender. In those aged 50 years or older, the prevalence of mass spectrometry was significantly higher in Black participants (224 [17%] of 1356) compared with the controls (p=0·0012) but not in those with family history (368 [13%] of 2851) compared with the controls (p=0·1008). Screen-detected monoclonal gammopathies correlated with increased all-cause mortality in MGBB participants (hazard ratio 1·55, 95% CI 1·16–2·08; p=0·0035). All monoclonal gammopathies were associated with an increased likelihood of comorbidities, including myocardial infarction (odds ratio 1·60, 95% CI 1·26–2·02; p=0·00016 for MGIP-high and 1·39, 1·07–1·80; p=0·015 for mass-spectrometry MGUS).
We detected a high prevalence of monoclonal gammopathies, including age-associated MGIP, and made more precise estimates of mass-spectrometry MGUS compared with conventional gel-based methods. The use of mass spectrometry also highlighted the potential hidden clinical significance of MGIP. Our study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival.
Stand Up To Cancer Dream Team, the Multiple Myeloma Research Foundation, and National Institutes of Health.</description><subject>Cohort Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Mass Spectrometry</subject><subject>Monoclonal Gammopathy of Undetermined Significance - epidemiology</subject><subject>Multiple Myeloma - epidemiology</subject><subject>Paraproteinemias - diagnosis</subject><subject>Paraproteinemias - epidemiology</subject><subject>Prevalence</subject><issn>2352-3026</issn><issn>2352-3026</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1TAQhS0EolXpI4C8LIu0_ondmA1CVaGVKoFUuracidNr8E-wnUr3NXhifHtLxY6VRzPf8WjOQegtJaeUUHl2y7hgHSdMnjD2nhAiVcdeoMPn9st_6gN0XMqPBlF-LoVUr9EBF7zv5aAO0e9v2T4YbyNYnGYcUkzgUzQe35sQ0mLqxtmCTZwweBcdtElaK6TQui5igzfuftNlV37iu1u8pGX1proUcYFsbbQTHrc4mFJwWSzU3IQ1bz80YVh9dWBjzRZD2qRccanrtH2DXs3GF3v89B6hu8-X3y-uupuvX64vPt10wKWoHR3FIAcOhClmxETlTCUY1hszqnEEGKf53PT9MIKiQnE10IFPYu5nqkASxfkROtn_u-T0a7Wl6uAKWO9NtGktmsm-V5KpgTRU7FHIqZRsZ71kF0zeakr0LhH9mIje2a0Z04-JaNZ0755WrGOw07Pqr_8N-LgHbDv0wdmsC7hdGJPLzS09JfefFX8Acu2drw</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>El-Khoury, Habib</creator><creator>Lee, David J</creator><creator>Alberge, Jean-Baptiste</creator><creator>Redd, Robert</creator><creator>Cea-Curry, Christian J</creator><creator>Perry, Jacqueline</creator><creator>Barr, Hadley</creator><creator>Murphy, Ciara</creator><creator>Sakrikar, Dhananjay</creator><creator>Barnidge, David</creator><creator>Bustoros, Mark</creator><creator>Leblebjian, Houry</creator><creator>Cowan, Anna</creator><creator>Davis, Maya I</creator><creator>Amstutz, Julia</creator><creator>Boehner, Cody J</creator><creator>Lightbody, Elizabeth D</creator><creator>Sklavenitis-Pistofidis, Romanos</creator><creator>Perkins, Mark C</creator><creator>Harding, Stephen</creator><creator>Mo, Clifton C</creator><creator>Kapoor, Prashant</creator><creator>Mikhael, Joseph</creator><creator>Borrello, Ivan M</creator><creator>Fonseca, Rafael</creator><creator>Weiss, Scott T</creator><creator>Karlson, Elizabeth</creator><creator>Trippa, Lorenzo</creator><creator>Rebbeck, Timothy R</creator><creator>Getz, Gad</creator><creator>Marinac, Catherine R</creator><creator>Ghobrial, Irene M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202205</creationdate><title>Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study</title><author>El-Khoury, Habib ; Lee, David J ; Alberge, Jean-Baptiste ; Redd, Robert ; Cea-Curry, Christian J ; Perry, Jacqueline ; Barr, Hadley ; Murphy, Ciara ; Sakrikar, Dhananjay ; Barnidge, David ; Bustoros, Mark ; Leblebjian, Houry ; Cowan, Anna ; Davis, Maya I ; Amstutz, Julia ; Boehner, Cody J ; Lightbody, Elizabeth D ; Sklavenitis-Pistofidis, Romanos ; Perkins, Mark C ; Harding, Stephen ; Mo, Clifton C ; Kapoor, Prashant ; Mikhael, Joseph ; Borrello, Ivan M ; Fonseca, Rafael ; Weiss, Scott T ; Karlson, Elizabeth ; Trippa, Lorenzo ; Rebbeck, Timothy R ; Getz, Gad ; Marinac, Catherine R ; Ghobrial, Irene M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-1b58683c0292a5d16f16ca24aab9bbccbdf7a448bc9159398183d5f4f19c60933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cohort Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Mass Spectrometry</topic><topic>Monoclonal Gammopathy of Undetermined Significance - epidemiology</topic><topic>Multiple Myeloma - epidemiology</topic><topic>Paraproteinemias - diagnosis</topic><topic>Paraproteinemias - epidemiology</topic><topic>Prevalence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El-Khoury, Habib</creatorcontrib><creatorcontrib>Lee, David J</creatorcontrib><creatorcontrib>Alberge, Jean-Baptiste</creatorcontrib><creatorcontrib>Redd, Robert</creatorcontrib><creatorcontrib>Cea-Curry, Christian J</creatorcontrib><creatorcontrib>Perry, Jacqueline</creatorcontrib><creatorcontrib>Barr, Hadley</creatorcontrib><creatorcontrib>Murphy, Ciara</creatorcontrib><creatorcontrib>Sakrikar, Dhananjay</creatorcontrib><creatorcontrib>Barnidge, David</creatorcontrib><creatorcontrib>Bustoros, Mark</creatorcontrib><creatorcontrib>Leblebjian, Houry</creatorcontrib><creatorcontrib>Cowan, Anna</creatorcontrib><creatorcontrib>Davis, Maya I</creatorcontrib><creatorcontrib>Amstutz, Julia</creatorcontrib><creatorcontrib>Boehner, Cody J</creatorcontrib><creatorcontrib>Lightbody, Elizabeth D</creatorcontrib><creatorcontrib>Sklavenitis-Pistofidis, Romanos</creatorcontrib><creatorcontrib>Perkins, Mark C</creatorcontrib><creatorcontrib>Harding, Stephen</creatorcontrib><creatorcontrib>Mo, Clifton C</creatorcontrib><creatorcontrib>Kapoor, Prashant</creatorcontrib><creatorcontrib>Mikhael, Joseph</creatorcontrib><creatorcontrib>Borrello, Ivan M</creatorcontrib><creatorcontrib>Fonseca, Rafael</creatorcontrib><creatorcontrib>Weiss, Scott T</creatorcontrib><creatorcontrib>Karlson, Elizabeth</creatorcontrib><creatorcontrib>Trippa, Lorenzo</creatorcontrib><creatorcontrib>Rebbeck, Timothy R</creatorcontrib><creatorcontrib>Getz, Gad</creatorcontrib><creatorcontrib>Marinac, Catherine R</creatorcontrib><creatorcontrib>Ghobrial, Irene M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet. Haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Khoury, Habib</au><au>Lee, David J</au><au>Alberge, Jean-Baptiste</au><au>Redd, Robert</au><au>Cea-Curry, Christian J</au><au>Perry, Jacqueline</au><au>Barr, Hadley</au><au>Murphy, Ciara</au><au>Sakrikar, Dhananjay</au><au>Barnidge, David</au><au>Bustoros, Mark</au><au>Leblebjian, Houry</au><au>Cowan, Anna</au><au>Davis, Maya I</au><au>Amstutz, Julia</au><au>Boehner, Cody J</au><au>Lightbody, Elizabeth D</au><au>Sklavenitis-Pistofidis, Romanos</au><au>Perkins, Mark C</au><au>Harding, Stephen</au><au>Mo, Clifton C</au><au>Kapoor, Prashant</au><au>Mikhael, Joseph</au><au>Borrello, Ivan M</au><au>Fonseca, Rafael</au><au>Weiss, Scott T</au><au>Karlson, Elizabeth</au><au>Trippa, Lorenzo</au><au>Rebbeck, Timothy R</au><au>Getz, Gad</au><au>Marinac, Catherine R</au><au>Ghobrial, Irene M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study</atitle><jtitle>The Lancet. Haematology</jtitle><addtitle>Lancet Haematol</addtitle><date>2022-05</date><risdate>2022</risdate><volume>9</volume><issue>5</issue><spage>e340</spage><epage>e349</epage><pages>e340-e349</pages><issn>2352-3026</issn><eissn>2352-3026</eissn><abstract>Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of European ancestry aged 50 years or older. MGUS prevalence is two times higher in individuals of African descent or with a family history of conditions related to multiple myeloma. We aimed to evaluate the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population screened by quantitative mass spectrometry.
We used quantitative matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry and EXENT-iQ software to screen for and quantify monoclonal gammopathies in serum from 7622 individuals who consented to the PROMISE screening study between Feb 26, 2019, and Nov 4, 2021, and the Mass General Brigham Biobank (MGBB) between July 28, 2010, and July 1, 2021. M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were confirmed by liquid chromatography mass spectrometry testing. 6305 (83%; 2211 from PROMISE, 4094 from MGBB) of 7622 participants in the cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a family history of haematological malignancies and fell within the eligible high-risk age range (30 years or older for PROMISE cohort and 18 years or older for MGBB cohort); those over 18 years were also eligible if they had two or more family members with a blood cancer (PROMISE cohort). Participants with a plasma cell malignancy diagnosed before screening were excluded. Longitudinal clinical data were available for MGBB participants with a median follow-up time from serum sample screening of 4·5 years (IQR 2·4–6·7). The PROMISE study is registered with ClinicalTrials.gov, NCT03689595.
The median age at time of screening was 56·0 years (IQR 46·8–64·1). 5013 (66%) of 7622 participants were female, 2570 (34%) male, and 39 (<1%) unknown. 2439 (32%) self-identified as Black, 4986 (65%) as White, 119 (2%) as other, and 78 (1%) unknown. Using serum protein electrophoresis with immunofixation electrophoresis, the MGUS prevalence was 6% (101 of 1714) in high-risk individuals aged 50 years or older. Using mass spectrometry, we observed a total prevalence of monoclonal gammopathies of 43% (1788 of 4207) in this group. We termed monoclonal gammopathies below the clinical immunofixation electrophoresis detection level (<0·2 g/L) MGIPs, to differentiate them from those with higher concentrations, termed mass-spectrometry MGUS, which had a 13% (592 of 4207) prevalence by mass spectrometry in high-risk individuals aged 50 years or older. MGIP was predominantly of immunoglobulin M isotype, and its prevalence increased with age (19% [488 of 2564] for individuals aged <50 years, 29% [1464 of 5058] for those aged ≥50 years, and 37% [347 of 946] for those aged ≥70 years). Mass-spectrometry MGUS prevalence increased with age (5% [127 of 2564] for individuals aged <50 years, 13% [678 of 5058] for those aged ≥50 years, and 18% [173 of 946] for those aged ≥70 years) and was higher in men (314 [12%] of 2570) compared with women (485 [10%] 5013; p=0·0002), whereas MGIP prevalence did not differ significantly by gender. In those aged 50 years or older, the prevalence of mass spectrometry was significantly higher in Black participants (224 [17%] of 1356) compared with the controls (p=0·0012) but not in those with family history (368 [13%] of 2851) compared with the controls (p=0·1008). Screen-detected monoclonal gammopathies correlated with increased all-cause mortality in MGBB participants (hazard ratio 1·55, 95% CI 1·16–2·08; p=0·0035). All monoclonal gammopathies were associated with an increased likelihood of comorbidities, including myocardial infarction (odds ratio 1·60, 95% CI 1·26–2·02; p=0·00016 for MGIP-high and 1·39, 1·07–1·80; p=0·015 for mass-spectrometry MGUS).
We detected a high prevalence of monoclonal gammopathies, including age-associated MGIP, and made more precise estimates of mass-spectrometry MGUS compared with conventional gel-based methods. The use of mass spectrometry also highlighted the potential hidden clinical significance of MGIP. Our study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival.
Stand Up To Cancer Dream Team, the Multiple Myeloma Research Foundation, and National Institutes of Health.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35344689</pmid><doi>10.1016/S2352-3026(22)00069-2</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2352-3026 |
| ispartof | The Lancet. Haematology, 2022-05, Vol.9 (5), p.e340-e349 |
| issn | 2352-3026 2352-3026 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2644962980 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Cohort Studies Female Humans Male Mass Spectrometry Monoclonal Gammopathy of Undetermined Significance - epidemiology Multiple Myeloma - epidemiology Paraproteinemias - diagnosis Paraproteinemias - epidemiology Prevalence |
| title | Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A53%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20monoclonal%20gammopathies%20and%20clinical%20outcomes%20in%20a%20high-risk%20US%20population%20screened%20by%20mass%20spectrometry:%20a%20multicentre%20cohort%20study&rft.jtitle=The%20Lancet.%20Haematology&rft.au=El-Khoury,%20Habib&rft.date=2022-05&rft.volume=9&rft.issue=5&rft.spage=e340&rft.epage=e349&rft.pages=e340-e349&rft.issn=2352-3026&rft.eissn=2352-3026&rft_id=info:doi/10.1016/S2352-3026(22)00069-2&rft_dat=%3Cproquest_cross%3E2644962980%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644962980&rft_id=info:pmid/35344689&rft_els_id=S2352302622000692&rfr_iscdi=true |